Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
NCT04950075Phase 2Active, not recruiting
- Sponsor
- Inhibrx Biosciences
- Start
- Sep 2021
- Primary completion
- Sep 2025
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of ozekibart in chondrosarcoma, sponsored by Inhibrx Biosciences. Started Sep 2021; status: active, not recruiting.
02
Drugs
ozekibart
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on NCT04950075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950075.